diethyl 2-[[5-[[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-methoxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]methyl]-1-methylimidazol-2-yl]methyl]butanedioate | 959162-96-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: diethyl 2-[[5-[[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-methoxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]methyl]-1-methylimidazol-2-yl]methyl]butanedioate
• CAS: 959162-96-0
• 化学式: C₂₉H₄₉N₅O₈
• 分子量: 595.737
• InChiKey: OCESLMFFPXTJSP-QQOZXCBMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  42
• 可旋转键数：
  21
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  167
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  diethyl 2-[[5-[[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-methoxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]methyl]-1-methylimidazol-2-yl]methyl]butanedioate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 2.0h， 以89%的产率得到N-[[2-(2,3-dicarboxypropyl)-1-methyl-1H-imidazol-5-yl]methyl]-L-valyl-L-isoleucyl-L-alanine
  参考文献：
  名称：

  蛋白质法呢基转移酶的潜在双底物抑制剂的合成和生物学评估。设计和合成功能化的咪唑。

  摘要：

  使用基于结构的设计，已经合成了一系列新的化合物，这些化合物衍生自2,5-官能化的咪唑，作为蛋白质法呢基转移酶（FTase）的潜在双底物抑制剂。这些化合物具有1，4-二酸链和通过咪唑环连接的三肽。合成策略依赖于杂环的C-2位具有二酸侧链的功能化和C-5位的肽偶联。以高收率合成了几种新化合物。活性最高的化合物的动力学实验表明，取决于二酸链长，结合方式不同。

  DOI：

  10.1039/b709854e
• 作为产物：
  描述：

  在 sodium cyanoborohydride 作用下， 以 甲醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 以160 mg的产率得到diethyl 2-[[5-[[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-methoxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]methyl]-1-methylimidazol-2-yl]methyl]butanedioate
  参考文献：
  名称：

  蛋白质法呢基转移酶的潜在双底物抑制剂的合成和生物学评估。设计和合成功能化的咪唑。

  摘要：

  使用基于结构的设计，已经合成了一系列新的化合物，这些化合物衍生自2,5-官能化的咪唑，作为蛋白质法呢基转移酶（FTase）的潜在双底物抑制剂。这些化合物具有1，4-二酸链和通过咪唑环连接的三肽。合成策略依赖于杂环的C-2位具有二酸侧链的功能化和C-5位的肽偶联。以高收率合成了几种新化合物。活性最高的化合物的动力学实验表明，取决于二酸链长，结合方式不同。

  DOI：

  10.1039/b709854e

文献信息

• INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS
  申请人：TABACZYNSKI David A.

  公开号：US20160303146A1

  公开（公告）日：2016-10-20

  This invention provides methods and pharmaceutical compositions that can treat neuroinflammatory disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS
  申请人：TABACZYNSKI David A.

  公开号：US20160375041A1

  公开（公告）日：2016-12-29

  The invention provides methods and pharmaceutical compositions that can treat autoimmune disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• [EN] INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS<br/>[FR] INHIBITION DE VOIES DE BIOSYNTHÈSE D'ISOPRÉNOÏDES POUR TRAITER DES TROUBLES AUTO-IMMUNS
  申请人：TABACZYNSKI DAVID A

  公开号：WO2015084721A1

  公开（公告）日：2015-06-11

  The invention provides methods and pharmaceutical compositions that can treat autoimmune disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• [EN] INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS<br/>[FR] INHIBITION DE VOIES DE BIOSYNTHÈSE D'ISOPRÉNOÏDES POUR TRAITER DES TROUBLES NEURO-INFLAMMATOIRES
  申请人：TABACZYNSKI DAVID A

  公开号：WO2015089349A1

  公开（公告）日：2015-06-18

  This invention provides methods and pharmaceutical compositions that can treat neuroinflammatory disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.